My NCBISign In
Logo of bloodcancerLink to Publisher's site

Volume 2(4);  April 2012

Original Articles

Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo
T Kiziltepe, J D Ashley, J F Stefanick, Y M Qi, N J Alves, M W Handlogten, M A Suckow, R M Navari, B Bilgicer
Blood Cancer J. 2012 April; 2(4): e64. Published online 2012 April 20. doi: 10.1038/bcj.2012.10
PMCID:
PMC3346680
Abstract Full Text PDF–692K Supplementary Material
Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model
F Mori, T Ishida, A Ito, F Sato, A Masaki, H Takino, M Ri, S Kusumoto, H Komatsu, R Ueda, H Inagaki, S Iida
Blood Cancer J. 2012 April; 2(4): e67. Published online 2012 April 20. doi: 10.1038/bcj.2012.12
PMCID:
PMC3346682
Abstract Full Text PDF–851K
Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
T Ishii, T Seike, T Nakashima, S Juliger, L Maharaj, S Soga, S Akinaga, J Cavenagh, S Joel, Y Shiotsu
Blood Cancer J. 2012 April; 2(4): e68. Published online 2012 April 27. doi: 10.1038/bcj.2012.13
PMCID:
PMC3346683
Abstract Full Text PDF–600K

Review

Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies
N K El-Mallawany, J K Frazer, P Van Vlierberghe, A A Ferrando, S Perkins, M Lim, Y Chu, M S Cairo
Blood Cancer J. 2012 April; 2(4): e65. Published online 2012 April 13. doi: 10.1038/bcj.2012.8
PMCID:
PMC3346681
Abstract Full Text PDF–1014K

Letter to the Editor

Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number
C Buors, N Douet-Guilbert, F Morel, L Lecucq, B Cassinat, V Ugo
Blood Cancer J. 2012 April; 2(4): e66. Published online 2012 April 13. doi: 10.1038/bcj.2012.11
PMCID:
PMC3346679
Full Text PDF–205K
Articles from Blood Cancer Journal are provided here courtesy of Nature Publishing Group
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk